Behind the Consultant Curtain: Leveraging Your Segment’s Strengths

Posted by Malik Kaman on Jan 8, 2018 8:00:00 AM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part two in a two-part series.

In our previous post, we discussed the four typical “segments” of oncology companies:

  1. Original Innovators: High prior oncology success, low commercial sophistication
  2. The Space Invaders: Low prior oncology success, high commercial sophistication
  3. The New Kids on the Block: Low prior oncology success, low commercial sophistication
  4. The Vanguard: High prior oncology success, high commercial sophistication

>
Read More

Behind the Consultant Curtain: What Kind of Oncology Company Are You?

Posted by Malik Kaman on Dec 12, 2017 2:21:03 PM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part one in a two-part series.

At ZS, we’ve advised companies on more than 90% of the launches in oncology over the past five years, so manufacturers frequently ask us how they compare to others in terms of their people, their processes and their capabilities. This is a great question. With the pace of oncology investment worldwide—oncology is expected to be 21.25% of total pharma sales in 2020 globally, according to a Quintiles analysis—the level of competition in this space has risen to a whole new level. As we think about what it will take to compete and win in the new reality, it’s important to consider the commercial advantages and disadvantages of who you are as a company—your people, processes and capabilities—not just what scientific innovations you can bring.


>
Read More

How to Pay for Transformative Cell and Gene Therapies

Posted by Bernadette Bourjolly on Oct 13, 2017 8:00:00 AM

Malik Kaman co-wrote this blog post with Bernadette Bourjolly. 

After two decades of failures and setbacks, it’s an exciting time in the field of cell and gene therapies as we witness pioneering advances in a wide range of indications in areas including blood cancers, immunodeficiency and ophthalmology. While cell and gene therapies represent a potential paradigm shift for the treatment of cancer and rare genetic disorders, funding and reimbursement of these unconventional therapies pose major challenges. 


>
Read More

Five Observations From Successful Oncology ‘First Launches’

Posted by Ben Hohn on Aug 14, 2017 10:29:32 AM

Nicholas Martinez and Cody Powers co-wrote this blog post with Ben Hohn.

The stakes are high when preparing to launch a new drug, but for a biopharmaceutical company staring down its first-ever oncology launch, the stakes are even higher. Drug launches in the oncology space have grown increasingly competitive and occur more frequently than in any other therapeutic category. And of the 202 novel drugs approved by the FDA from 2011 to 2016, five were oncology drugs launched in the U.S. by publicly traded newcomers—so-called “first launches.”  


>
Read More

The Promise of CAR-T: Three Strategies for Getting Next-Wave Cancer Medicines to Patients in Need

Posted by Namita Kalyan on May 10, 2016 8:00:00 AM

After initial concerns and disappointing studies in the 1980s to early 2000s, cell and gene therapies are now at the forefront of medicine, displaying unprecedented efficacy in a number of clinical trials. As more trials occur, the patient success stories are growing, and an increasing number of manufacturers are investing or partnering to develop more of these next-wave cancer medicines. In 2015, close to 100 clinical trials involving CAR (chimeric antigen receptor) T-cell therapies were under development, according to the Journal of Immunology Research.


>
Read More